Skip to content
Search

Latest Stories

Prefer paracetamol to ibuprofen to treat COVID-19 symptoms, NHS advises

There currently is no evidence which links anti-inflammatory medicines such as ibuprofen with the worsening of COVID-19, NHS said on Wednesday.

The agency, however, advised to take paracetamol to treat symptoms of COVID-19, until more information is available, adding that regulatory agencies are reviewing the evidence.


“In view of the current lack of clarity the Committee of Human Medicines (an advisory body of MHRA) and NICE have been asked to review the evidence,” said Stephen Powis, medical director at NHS England.

“It is therefore suggested that, in the interim, for patients, who have confirmed COVID-19 or believe they have COVID-19, that they use paracetamol in preference to NSAIDs (non-steroidal anti-inflammatory drugs).”

Powis added that patients already being treated with anti-inflammatory drugs for other medical reasons should not stop them.

The World Health Organization on Tuesday recommended that people suffering from COVID-19-like symptoms should avoid self-medicating with ibuprofen, after French authorities warned anti-inflammatory drugs could worsen the effects of the virus.

The warnings over the weekend by French Health Minister Olivier Veran, a clinician himself, followed a recent study in The Lancet weekly medical journal that hypothesised that an enzyme that is boosted when taking anti-inflammatory drugs like ibuprofen could facilitate and worsen COVID-19 infections.

Reckitt Benckiser (RB), the makers of Nurofen products, said it is aware of "the ongoing spread of information" concerning the use of NSAIDs including ibuprofen, but requested patients and healthcare professionals to consider each case separately.

The firm said all available treatment options, including paracetamol and NSAIDs, should be considered when starting treatment for fever or pain in COVID-19, noting that the European Medicines Agency (EMA), World Health Organisation as well as NHS has stated that there is currently no strong scientific evidence linking ibuprofen usage to worsening of COVID-19.

"Consumer safety is our number one priority. Ibuprofen is a well-established medicine that has been used with a good safety profile as a fever and pain reducer for more than 30 years," it said.

The EMA on Wednesday said that there currently is no evidence to link anti-inflammatory medicines such as ibuprofen with the worsening of COVID-19.

The EU regulator added that it was monitoring the situation, but took a similar tone to RB in suggesting patients and healthcare professionals to consider all treatment options including paracetamol and anti-inflammatory drugs to treat fever or pain in patients with COVID-19.

The COVID-19 pandemic causes mild symptoms in most people, but can result in pneumonia and in some cases severe illness that can lead to multiple organ failure.

More For You

Antibiotic prescribing for sore throats in England's pharmacies is twice as high as in Wales

Antibiotic supply rate was 72.7% under England’s Acute Sore Throat Pharmacy First compared to just 29.9% under Wales’ Sore Throat Test and Treat (STTT) scheme in six months.

Getty Images

Sore throat treatment: England pharmacies twice as likely to prescribe antibiotics as Welsh counterparts

A new study has highlighted significant differences in antibiotic use for sore throat treatment between pharmacies in England and Wales, suggesting that incorporating throat swabs to confirm bacterial infections could help reduce “unnecessary antibiotic supply.”

The study, published in the Journal of Antimicrobial Chemotherapy and first reported by The Independent, found that pharmacies in England were twice as likely to prescribe antibiotics for sore throats compared to those in Wales.

Keep ReadingShow less
GPs to play crucial role in transforming Wales’ health service

Jeremy Miles

(Photo credit: www.gov.wales )

Strengthening GPs’ role key to transforming healthcare - Jeremy Miles

Welsh health secretary Jeremy Miles has recognised the need to transform health services and bring healthcare closer to home.

Speaking at the recent Welsh Local Medical Committees Conference, he emphasised that strengthening the role of GPs would be crucial in improving patient healthcare and tackling NHS waiting lists.

Keep ReadingShow less
NPA and IPA urge NHS England to release pharmacy economic analysis immediately

Pharmacy bodies call for transparency on the funding gap amid ongoing contract negotiations.

Getty Images

Pharmacy bodies demand immediate release of economic analysis

The National Pharmacy Association (NPA) and the Independent Pharmacies Association (IPA) have jointly written to NHS England, demanding the immediate release of the independent economic analysis of pharmacy finances commissioned last autumn.

An open letter, signed by the owners of 3,034 pharmacies in England, calls for transparency on the funding gap amid ongoing contract negotiations.

Keep ReadingShow less
Discrimination: Asian and Black patients report lack of trust in primary care providers

Ethnic minority groups had worse experiences in their communication with their GP practice and felt taken less seriously

Getty Images

Survey reveals alarming rates of ethnic discrimination in NHS primary care

A recent survey by the NHS Race and Health Observatory has highlighted a worrying lack of trust in NHS primary care services among Black, Asian, and ethnic minority patients, who reported experiencing “racial or ethnic discrimination.”

Out of 2,680 survey respondents, only 55% reported trusting primary care providers to meet their health needs most or all of the time

Keep ReadingShow less